FDA New Inhaled Product Guidelines: Bioequivalence & PSGs
Explore Nanopharm & Fluidda discuss FDA’s revised inhaled product guidelines (PSGs) and alternative bioequivalence pathways for generics.
Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
Dry Powder Inhaler Formulations: Microstructural Analysis Techniques
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Exploring PBPK Modeling in Nasal Drug Delivery: Expert Insights from Will Ganley
Explore PBPK modeling for OINDP and nasal drug delivery, optimizing drug development and reducing clinical trial needs
Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Optimising batch selection to increase success of PK studies for bioequivalence
Uncover Nanopharm’s SmartTrack approach for successful Pharmacokinetic and Bioequivalence studies in OINDP, using PBPK modelling.
Nanopharm Newsletter May 2023
Explore Nanopharm’s SmartTrack™ for OINDPs and uncover the role of PBPK in nasal drug delivery.
Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery
Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.
Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics
Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.
